The drugmaker’s on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
The drugmaker’s on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.